Transtoxbio portfolio finds client in OncoSeek Bio Pvt. Ltd.’s preclinical Discovery and Services

As part of this engagement OSB sources various cells and cellular platforms from Transtoxbio portfolio to enable its in-house exploratory R&D, discovery and screening on novel platforms that use various monolayers or 3D structures including spheroids/organoids/microfluidics and other printed technologies. OSB also plans to use Transtoxbio’s new league of human sourced primary mature cells and primary stem cells (CD34+ cells - TRANS-HSC) in generating new relevant animal models for several disease conditions that have no true preclinical animal model representation currently for pharmaceutical research. OSB is keen to treat Transtoxbio portfolio as itsmain cell based platforms or free suspended cells supplier for all its preclinical models and services to be offered to global industry and for its own discovery programs.